Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Phase III Study Of Gilead's Darusentan For Resistant Hypertension Meets Primary Endpoints (Medical News Today) |
 |
 |
|
Gilead Sciences, Inc. (Nasdaq: GILD) announced that DAR-311 (DORADO), a Phase III clinical trial evaluating the company's endothelin receptor antagonist (ERA) darusentan for the treatment of resistant hypertension, met its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and trough sitting diastolic blood pressure (DBP). |
